Jason Mccarthy


Maxim Shines Light on Galena Biopharma Inc (GALE) as Shares Surge 12%

Galena Biopharma Inc (NASDAQ:GALE) shares are climbing almost 12% today after the biotech firm presented data from its Phase 1b trial that evaluates patient’s …

Maxim Weighs in on Galena Biopharma Inc (GALE) Following ESMO Abstract Release

In a research report issued Monday, Maxim analyst Jason McCarthy reiterated a Buy rating on Galena Biopharma Inc (NASDAQ:GALE) with a price target of …

Maxim Boosts Price Target on bluebird bio Inc (BLUE) Following MSTX Vepoloxamer Failure

Maxim analyst Jason McCarthy is out with a research report on shares of bluebird bio Inc (NASDAQ:BLUE) discussing the aftermath of Mast Therapeutics’ (NYSEMKT:MSTX) …

Maxim Heads to Sidelines on Mast Therapeutics Inc (MSTX) in Wake of Disappointing Phase III Failure

Mast Therapeutics Inc (NYSEMKT:MSTX) announced yesterday that its phase III EPIC study results proved to be a “surprising disappointment,” after the firm’s pipeline …

Maxim’s Take on Mast Therapeutics Inc (MSTX) Following 5th Annual Sickle Cell Therapeutics Conference

All sickle cell community and investor eyes are on Mast Therapeutics (NYSEMKT:MSTX) this month, as MSTX prepares to roll out pivotal data from …

Here’s Why Maxim Downgraded Momenta Pharmaceuticals, Inc. (MNTA) to Sell

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) shares are tumbling 4% today, with sales for its generic copaxone (glatopa), an injection designed to treat patients with …

Maxim Dives in on Mast Therapeutics Inc (MSTX) Following Recent Stock Price Movement

In the past week, Mast Therapeutics Inc (NYSEMKT:MSTX) stock has seen a price increase from $0.40 to $0.

Maxim Slashes Price Target on Galena Biopharma Inc (GALE) Following 2Q:16 Update

Maxim analyst Jason McCarthy provides insight on shares of Galena Biopharma Inc (NASDAQ:GALE) after the company posted second-quarter results. While McCarthy reiterates a Buy …

Maxim Comments on Inovio Pharmaceuticals Inc (INO) as Ebola Vaccine Study Expands

Maxim analyst Jason McCarthy weighed in with a few insights on Inovio Pharmaceuticals Inc (NASDAQ:INO), after the company announced that the phase I study …

Maxim Chimes In on Mast Therapeutics Inc (MSTX) Following 2Q16 Update

In a research note released Tuesday, Maxim analyst Jason McCarthy reiterated a Buy rating on shares of Mast Therapeutics Inc (NYSEMKT:MSTX), with a $5.00 price target, …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts